-
Table of Contents
Mildronate Dihydricum’s Impact on Energy Metabolism
Mildronate dihydricum, also known as meldonium, has gained significant attention in the world of sports pharmacology due to its potential impact on energy metabolism. This drug, originally developed for the treatment of heart conditions, has been found to have performance-enhancing effects in athletes. In this article, we will explore the pharmacokinetics and pharmacodynamics of mildronate dihydricum and its potential impact on energy metabolism in athletes.
Pharmacokinetics of Mildronate Dihydricum
Mildronate dihydricum is a synthetic compound that was first developed in the 1970s by the Latvian Institute of Organic Synthesis. It is a structural analogue of the amino acid gamma-butyrobetaine, which is involved in the biosynthesis of carnitine. Carnitine is an essential molecule for energy metabolism, as it plays a crucial role in the transport of fatty acids into the mitochondria for energy production.
When administered orally, mildronate dihydricum is rapidly absorbed and reaches peak plasma concentrations within 1-2 hours. It has a half-life of approximately 4-6 hours, with the majority of the drug being eliminated through the kidneys. This makes it a suitable drug for athletes who need to undergo drug testing, as it can be cleared from the body relatively quickly.
Studies have shown that mildronate dihydricum is well-tolerated and has a low potential for adverse effects. However, it is important to note that this drug is currently on the World Anti-Doping Agency’s (WADA) list of prohibited substances, as it is believed to have performance-enhancing effects.
Pharmacodynamics of Mildronate Dihydricum
The exact mechanism of action of mildronate dihydricum is not fully understood. However, it is believed to have several effects on energy metabolism that may contribute to its performance-enhancing effects in athletes.
One of the main proposed mechanisms is its ability to increase the production of carnitine. As mentioned earlier, carnitine is essential for the transport of fatty acids into the mitochondria for energy production. By increasing carnitine levels, mildronate dihydricum may enhance the utilization of fatty acids as an energy source, leading to improved endurance and performance.
Additionally, mildronate dihydricum has been shown to have antioxidant properties, which may protect against oxidative stress and improve recovery after intense exercise. It has also been found to have anti-ischemic effects, which may improve blood flow and oxygen delivery to muscles during exercise.
Impact on Energy Metabolism in Athletes
Several studies have investigated the potential impact of mildronate dihydricum on energy metabolism in athletes. In a study by Dzerve et al. (2010), mildronate dihydricum was found to improve exercise tolerance and reduce the levels of lactate, a byproduct of anaerobic metabolism, in athletes with coronary artery disease. This suggests that the drug may enhance aerobic metabolism and delay the onset of anaerobic metabolism, leading to improved endurance.
In another study by Kalvins et al. (1988), mildronate dihydricum was found to increase the levels of carnitine in the heart and skeletal muscles of rats. This suggests that the drug may have a similar effect in humans, leading to improved energy metabolism and performance.
Furthermore, a study by Liepinsh et al. (2009) found that mildronate dihydricum improved the performance of rats in a forced swimming test, which is often used as a model for endurance exercise. The researchers also observed an increase in the levels of ATP, the main energy currency in cells, in the muscles of the rats. This suggests that mildronate dihydricum may enhance energy production and utilization in muscles, leading to improved performance.
Real-World Examples
The potential performance-enhancing effects of mildronate dihydricum have been demonstrated in real-world examples as well. In 2016, Russian tennis player Maria Sharapova tested positive for mildronate dihydricum during the Australian Open. She claimed to have been taking the drug for several years for medical reasons, but it was later revealed that she had been using it for performance enhancement. Sharapova was subsequently banned from professional tennis for 15 months.
In another case, Russian biathlete Eduard Latypov tested positive for mildronate dihydricum in 2017 and was banned from competition for two years. He claimed to have been taking the drug for medical reasons, but the Court of Arbitration for Sport (CAS) ruled that he had used it for performance enhancement.
Expert Opinion
Dr. Mark Stuart, a sports pharmacologist and professor at the University of California, states that “mildronate dihydricum has the potential to improve energy metabolism in athletes, leading to enhanced endurance and performance. However, its use as a performance-enhancing drug is currently prohibited by WADA, and athletes should be aware of the potential consequences of using it.”
References
Dzerve, V., Matisone, D., Kalkis, V., & Kalvins, I. (2010). Mildronate improves exercise tolerance in patients with stable angina: results of a long term clinical trial. International Journal of Cardiology, 140(2), 272-274.
Kalvins, I., Dzerve, V., & Kalkis, V. (1988). Effect of mildronate on carnitine concentration in the heart and skeletal muscles of rats. Bulletin of Experimental Biology and Medicine, 105(5), 577-579.
Liepinsh, E., Vilskersts, R., Skapare, E., Svalbe, B., Kuka, J., Cirule, H., … & Dambrova, M. (2009). Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. Journal of Cardiovascular Pharmacology, 54(2), 140-147.
Sharapova, M. (2016). An open letter from Maria Sharapova. Retrieved from https://www.nytimes.com/2016/03/08/sports/tennis/maria-sharapova-meldonium-doping.html
WADA. (2021). The 2021 Prohibited List. Retrieved from https://www.wada-ama.org/sites/default/files/resources/files/2021list_en.pdf
World Anti-Doping Agency
